Beijing Hotgen Biotech Co., Ltd. (688068.SS)
CNY 120.74
(5.36%)
CNY 120.74
(5.36%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 308.25 Million CNY | -83.87% |
| 2022 | 1.91 Billion CNY | -40.24% |
| 2021 | 3.19 Billion CNY | 887.9% |
| 2020 | 323.58 Million CNY | 110.31% |
| 2019 | 153.86 Million CNY | 11.5% |
| 2018 | 137.99 Million CNY | 31.1% |
| 2017 | 105.25 Million CNY | 13.28% |
| 2016 | 92.91 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q3 | 77.04 Million CNY | 38.1% |
| 2024 Q2 | 55.78 Million CNY | -18.63% |
| 2024 Q1 | 68.55 Million CNY | 44.86% |
| 2023 Q1 | 141.79 Million CNY | -38.02% |
| 2023 FY | 308.15 Million CNY | -83.87% |
| 2023 Q4 | 47.32 Million CNY | -18.12% |
| 2023 Q3 | 57.79 Million CNY | -5.62% |
| 2023 Q2 | 61.23 Million CNY | -56.81% |
| 2022 Q1 | 856.3 Million CNY | -0.98% |
| 2022 Q2 | 308.06 Million CNY | -64.02% |
| 2022 Q4 | 228.75 Million CNY | -55.77% |
| 2022 Q3 | 517.15 Million CNY | 67.87% |
| 2022 FY | 1.91 Billion CNY | -40.24% |
| 2021 Q3 | 52.55 Million CNY | -96.42% |
| 2021 Q2 | 1.46 Billion CNY | 80.73% |
| 2021 Q1 | 811.93 Million CNY | 262.56% |
| 2021 FY | 3.19 Billion CNY | 887.9% |
| 2021 Q4 | 864.81 Million CNY | 1545.42% |
| 2020 Q4 | 223.94 Million CNY | 520.18% |
| 2020 FY | 323.58 Million CNY | 110.31% |
| 2020 Q1 | 29.02 Million CNY | -46.13% |
| 2020 Q3 | 36.11 Million CNY | 4.64% |
| 2020 Q2 | 34.5 Million CNY | 18.91% |
| 2019 FY | 153.86 Million CNY | 11.5% |
| 2019 Q3 | 32.39 Million CNY | -21.26% |
| 2019 Q2 | 41.14 Million CNY | 55.54% |
| 2019 Q1 | 26.45 Million CNY | -44.38% |
| 2019 Q4 | 53.86 Million CNY | 66.27% |
| 2018 Q3 | 29.24 Million CNY | 0.0% |
| 2018 FY | 137.99 Million CNY | 31.1% |
| 2018 Q4 | 47.55 Million CNY | 62.65% |
| 2018 Q1 | 25.1 Million CNY | 0.0% |
| 2017 FY | 105.25 Million CNY | 13.28% |
| 2016 FY | 92.91 Million CNY | 0.0% |